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Abstract 
A comprehensive literature review was performed to evaluate the effect of various hormonal 
therapies, in terms of variations of intestinal and pain complaints and of patient satisfaction with 
treatment, in women with symptomatic, non-severely sub-occlusive endometriosis infiltrating the 
proximal rectum and sigmoid colon. A MEDLINE search through PubMed from 2000 to 2018 was 
conducted to identify all original English language articles published on medical treatment for 
colorectal endometriosis. Additional reports were identified by systematically reviewing reference 
lists and using the "similar articles" function in PubMed. A total of 420 women with colorectal 
endometriosis treated with combined oral contraceptives, progestins, gonadotropin releasing-
hormone (GnRH) agonists, and aromatase inhibitors have been described in eight case series, two 
retrospective cohort studies, and four case reports. Published data consistently suggest that several 
hormonal medications can control most symptoms associated with intestinal endometriosis, 
provided the relative bowel lumen stenosis is less than 60%. Patients with irritative-type symptoms 
appear to respond better than those with constipation. Overall, about two thirds of women were 
satisfied with the treatment received, independently of the drug used. Progestins are the compound 
supported by the largest body of evidence. The addition of aromatase inhibitors or, alternatively, the 
use of GnRH agonists, do not seem to be associated with better outcomes. Long-term treatment 
with a progestin should be proposed as an alternative to surgery to patients with non-severely sub-
occlusive endometriosis infiltrating the proximal rectum and sigmoid colon not seeking conception. 
The final decision should be shared together with the woman, respecting her preferences and 
priorities. 
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Abbreviations  
GnRH = gonadotropin releasing-hormone; 
 NETA = nor-ethisterone acetate;  
OC = oral contraceptive. 
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Key message 
According to the findings of case series and cohort studies, low-dose estrogen-progestins and 
progestins relieved intestinal symptoms in around two thirds of women with non-severely sub-
occlusive colorectal endometriosis, thus constituting an alternative to surgery in selected women 
not seeking conception. 
 
Introduction  
Deep bowel endometriosis, i.e., endometriosis infiltrating the intestinal muscular layer (1), appears 
to affect about one tenth of women with the endometriotic disease (2,3). When endometriosis 
causes bowel obstruction or severe sub-occlusion, surgery is the only reasonable choice. However, 
most patients with deep bowel endometriosis complains of cyclic and non-cyclic symptoms, such as 
abdominal bloating, intestinal cramping, diarrhea, and constipation, without obvious obstruction to 
stool passage (Figures 1 and 2). Symptoms may be associated not only with the degree of 
endometriotic infiltration and bowel lumen restriction, but also with lesion localization (1,4). The 
rectosigmoid colon is the most frequently involved intestinal tract, followed by isolated nodules of 
the proximal sigmoid, and by lesions of the terminal ileus and cecum (3,5,6).  
 According to some authors, excisional surgery is the best solution for women with 
symptomatic intestinal endometriosis, as medical treatments may exert an effect on the 
endometrial and smooth muscle component of the nodule, but not on the extensive fibrotic 
component, thus providing limited benefit (3,7-9). However, several investigators observed 
substantial improvements of bowel symptoms during hormonal treatment (10-14). Disentangling the 
uncertainties on the role of medical therapy in women with infiltrating bowel endometriosis seems 
exceedingly important, as excisional procedures with opening of the bowel lumen are generally 
effective in relieving intestinal symptoms, but are also associated with severe short- and long-term 
complications in about one patient out of 10 (e.g., intestinal leakage, anastomosis dehiscence, septic 
peritonitis, rectovaginal fistula formation, bowel anastomosis stenosis, iatrogenic neurologic bladder 
dysfunction with need for long periods of self-catheterization, and postoperative constipation and 
de-novo rectal dysfunction) (16-25). The incidence of some complications is associated also with the 
distance between the lower margin of resection and the anal verge (9,26). Thus, defining the 
localization of the lesion is important for limiting selection bias when comparing treatments in a 
research setting, and for counselling women when taking a decision in a clinical setting (9,15-
20,26,27). 
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 Given this background and the lack of consensus regarding the role of hormonal treatments 
for bowel endometriosis, we deemed opportune to synthetize the available evidence on the 
outcome of various medical therapies that have been used in patients with symptomatic, non-
severely sub-occlusive lesions. As hormonal treatments for endometriosis generally suppress 
ovulation (28), the findings presented in this review may be used to inform and counsel specifically 
women not seeking conception. 
 
Material and methods 
The objective of the present comprehensive review was the evaluation of the effect of various 
hormonal therapies, in terms of variations of intestinal and pain complaints as well as of patient 
satisfaction with treatment, in women with symptomatic colorectal endometriosis. 
 The aim was to identify reports of studies including patients with an instrumental diagnosis 
of endometriosis infiltrating the muscular layer of the proximal rectal tract (≥ 8 cm from the anal 
verge), the rectosigmoid junction (13 to 15 cm from the anal verge) and the sigmoid (> 15 cm from 
the anal verge). Studies focusing specifically on nodules of the distal rectum (within 8 cm from the 
anal verge) were not considered, as these lesions constitute part of rectovaginal endometriotic 
plaques (29). Stenotic occlusion of the rectal ampulla is exceedingly rare, due to its large caliber and 
distensibility. Moreover, differently from the proximal third of the rectum (upper rectum), the mid-
rectum, that corresponds to the Douglas' pouch, only has an anterior peritoneal covering. This 
renders sharp angulation, a determinant of bowel occlusion caused by endometriosis, mechanically 
unlikely if not impossible (15). In addition, the symptoms associated with endometriotic nodules of 
the mid- low-rectum are dyschezia and tenesmus, which are specific of lesions of the ampulla (30). 
Owing to the clinical differences with other endometriotic lesions of the proximal large bowel tract, 
the effect of medical therapies on nodules of the distal rectum has been already reported separately 
in another review (31).  
 A MEDLINE search through PubMed from January 2000 to January 2018 was conducted 
using combinations of medical subject heading terms "colorectal endometriosis", "intestinal 
endometriosis", "bowel endometriosis", "medical treatment", "combined oral contraceptives", 
"progestins", "GnRH agonists", "danazol", and "aromatase inhibitors". Only articles written in English 
and published in peer-reviewed journals were included, and the relative reference lists were 
systematically reviewed in order to identify further reports. Additional articles were searched using 
the "similar articles" function in PubMed. Information was extracted on study design, number of 
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treated patients, type of intestinal lesions, type of hormonal drugs used, treatment period, adverse 
events, types of questionnaires administered to assess bowel symptoms and function, and overall 
clinical outcome. 
Results 
A total of 420 women with large bowel endometriosis treated with combined oral contraceptives 
(OC), progestins, gonadotropin releasing-hormone (GnRH) agonists, and aromatase inhibitors have 
been described in 14 articles published in the period 2000-2018. Eight studies were case series 
(seven prospective, one retrospective) (10-14,32-34), two were retrospective cohort studies (29,35), 
and four were case reports (36-39) (Table 1). The precise location of lesions has not been 
systematically specified, and sometimes what was exactly intended with "colorectal endometriosis" 
is unclear. This terminology appears to have been used for different clinical situations, and not 
exclusively in cases of sigmoid and recto-sigmoid junction endometriosis, but also in cases of rectal 
nodules, which should be more properly included in the category of rectovaginal lesions or Douglas 
pouch lesions infiltrating the anterior rectal wall (15,29,31). The duration of medical treatment was 
three months in two studies, six months in three, 12 months in five, and > 12 months in four, 
including the two cohort studies. 
Estrogen-progestins and progestins 
Ferrari et al. (12) treated 26 patients with colorectal endometriotic lesions infiltrating the tunica 
muscularis with a low-dose, monophasic OC used continuously for 12 months. The lesion, as 
assessed at rectal endoscopic ultrasonography, was within 5 cm from the anal rim in 4 cases, 
between 5 and 10 cm in 14, and above 10 cm in eight. Women with an intestinal lumen stenosis 
more than 50% were excluded. Symptoms progressively improved and the nodule volume decreased 
by 62% at the end of the study. At 1-year evaluation, 18 patients (69%) were satisfied or very 
satisfied with their treatment, four were uncertain, and four were dissatisfied or very dissatisfied. 
Millochau et al. (38) reported the case of a woman treated with estrogen-progestin combinations for 
an isolated nodule of the sigmoid colon that grew during a 4-year medical treatment causing 
occlusive symptoms and necessitating surgery. 
 Egekvist et al. (35) conducted a retrospective cohort study in one of the two Danish tertiary 
referral centers in which treatment of advanced endometriosis is allowed by the national health 
authority. Patients treated medically or surgically for rectosigmoid lesions were identified in the 
electronic patient record system according to ICD10 codes for endometriosis affecting the 
rectosigmoid, vagina or the rectovaginal septum. Of the 238 women with rectosigmoid 
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endometriosis verified by transvaginal ultrasonography and/or magnetic resonance imaging, 78 
(33%) underwent immediate surgery, whereas 160 were treated medically with OCs, a 
levonorgestrel-releasing- intra-uterine device, or oral progestins. After a median follow-up of 22 
months, 27 of the 160 (17%) patients initially treated medically necessitated surgery. Overall, 
133/238 (56%) women with rectosigmoid endometriosis could be managed successfully with 
hormone manipulation, and about four out of five women (133/160; 83%) for whom a medical 
treatment was decided at baseline evaluation, eventually avoided surgery. 
 The largest evidence on the effect of progestins for bowel endometriosis is derived from 
studies on the use of nor-ethisterone acetate (NETA) and dienogest. Ferrero et al. (11) enrolled 40 
patients with nodules infiltrating the sigmoid (n = 18), the recto-sigmoid junction (n = 12), and the 
rectum (n = 10). The diagnosis was based on multidetector computed tomography  enteroclysis, and 
women with of a stenosis of the bowel lumen greater than 60% were excluded. Nor-ethisterone 
acetate determined relief from symptoms related to the menstrual cycle, including constipation, 
diarrhea, and cyclical rectal bleeding. The severity of diarrhea, intestinal cramping and passage of 
mucus also significantly improved during treatment. However, progestin therapy did not 
substantially ameliorate constipation, abdominal bloating and feeling of incomplete evacuation after 
bowel movements. Overall 21/40 patients (53%) referred some improvement in gastrointestinal 
symptoms. At 1-year evaluation, 60% of participant were satisfied or very satisfied with their 
treatment, 20% were uncertain, and 20% were either dissatisfied or very dissatisfied. 
 The effect of dienogest in patients with bowel endometriosis was assessed by the same 
research group in two case series. Yela et al. (13) treated 16 women with rectovaginal or bowel 
endometriosis with dienogest, 2mg/day for six months. All participants had already used other 
progestins without improvement of pain. It is unclear whether all the participants had intestinal 
lesions and which was the exact lesion location. The mean volume of the intestinal nodule decreased 
from 3.4 cc at baseline to 1.6 cc at the end of treatment. A significant reduction in defecation pain, 
referred by 69% of the patients at baseline, was observed from the second month of therapy.  
 Leonardo-Pinto et al. (14) evaluated the effect of dienogest prescribed for 12 months in 30 
women with rectovaginal and bowel endometriosis. At baseline, participants referred persistent 
pain complaints despite medical treatment with other progestins for at least six months. Also in this 
case, whether all the patients had intestinal lesions and at which level was not specified. Intestinal 
pain decreased significantly during the study period but, at odds with their previous experience (35), 
the authors did not observe a significant reduction in bowel lesions size. 
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 Dienogest was used also by Tamura et al. (37) and Ng et al. (39) in two women with 
endometriosis located at the proximal rectum and rectosigmoid junction. Substantial bowel 
symptom improvement and lesion size reduction were observed in both patients after, respectively, 
22- and six-month progestin treatment. 
 A parallel cohort study was conducted on 87 women with colorectal endometriosis not 
causing persistent and severe sub-occlusive symptoms, to investigate whether an OC or a progestin 
are a satisfactory alternative to surgery in women who choose their treatment after a standardized 
shared decision-making process (29). A total of 50 patients chose treatment with a low-dose, 
monophasic OC (n = 12) or a progestin (nor-ethisterone acetate, 2.5 mg/day or dienogest, 2 mg/day; 
n = 38), whereas 37 women confirmed their previous indication to surgery. Six women in the medical 
treatment group requested surgery because of drug inefficacy or intolerance. Seven major 
complications (19%) were observed in the surgery group. At 12-month follow-up, 39 (78%) women in 
the OC/progestin group were satisfied with their treatment, compared with 28 (76%) in the surgery 
group (intention-to-treat analysis). Corresponding figures after a median follow-up of, respectively, 
40 and 45 months, were 72% in the former group and 65% in the latter one. The 60-month 
cumulative proportion of dissatisfaction-free participants was 71% in the OC/progestin group 
compared with 61% in the surgery group. Bowel symptoms were improved by both treatments.  
GnRH agonists 
Porpora et al. (36) treated with leuprolide acetate in a monthly depot formulation, a woman with 
sigmoid endometriosis and observed symptom remission and lesion disappearance at 6-month 
follow-up colonoscopy.  
 The effect of a GnRH agonist (triptorelin in a depot 3-monthly formulation) with add-back 
therapy (oral tibolone, 2.5 mg/day) for 12 months was assessed by Ferrero et al. (10) in 18 women 
with endometriotic nodules infiltrating the sigmoid (n = 9), the recto-sigmoid junction (n = 5), and 
the rectum (n = 4). The larger colorectal nodule had a mean diameter of 2.2 ± 0.6 cm and the mean 
degree of stenosis of the bowel lumen was 42.0% ± 9.7%. Intestinal symptoms improved during 
treatment in 11 (61%) women, whereas in 7 (39%) the intestinal function did not change. In 
particular, patients with symptoms mimicking diarrhea-predominant irritable bowel syndrome 
benefitted more from GnRH agonist treatment compared with those complaining of symptoms 
mimicking constipation-predominant irritable bowel syndrome. In fact, abdominal bloating, 
intestinal cramping, and passage of mucus improved, but feeling of incomplete evacuation did not 
vary. At 1-year evaluation, 13 (72%) women were satisfied with their treatment. 
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Roman et al. (34) evaluated the effect of one i.m. depot injection of triptorelin 11.25 mg plus 
one daily dose of percutaneous estradiol 0.1% as a preoperative measure in 70 patients with an 
endometriotic rectal nodule infiltrating at least the muscular layer and up to 15 cm above the anus. 
The rectal lesions were identified at endo-rectal ultrasonography, and a computed tomography-
based virtual colonoscopy was performed to identify bowel lumen stenosis and additional intestinal 
tract localizations. After three months of therapy, cyclic digestive complaints were relieved in more 
than half of the women (defecation pain, 57%; abnormal frequency of bowel movements, 43%; 
bloating, 36%), whereas constipation and non-cyclic symptoms were improved in less than a third of 
patients. Subjective improvement was unrelated with rectal nodule volume.  
Aromatase inhibitors 
An aromatase inhibitor was used by Ferrero et al. (32) in six women with bowel nodules infiltrating 
at least the tunica muscularis, but with lumen stenosis less than 60%. Four patients complained of 
intestinal cramping, three of abdominal bloating, three of symptoms mimicking irritable bowel 
syndrome (e.g., diarrhea), two of constipation, two of passage of mucus in the stools, and one of 
cyclic rectal bleeding. The patients received oral letrozole (2.5 mg/day) combined with NETA (2.5 
mg/day) to prevent ovarian stimulation. All symptoms improved during the 6-month treatment, 
except constipation. At final assessment, four women (67%) were satisfied with the treatment 
received and declared that gastrointestinal symptoms were improved.  
 
Discussion 
Compared with superficial peritoneal endometriosis, deep endometriosis has a distinct histological 
characteristic as, in addition to the ectopic endometrial-like mucosa (endometrial epithelium and 
stroma), and the fibrotic component deriving from inflammation (caused by the metabolic activity of 
the ectopic endometrium and repeated micro-hemorrhages), smooth muscle fibers are also present 
(44). This is expected because the so-called deep endometriosis infiltrates the wall of hollow viscera 
such as the bowel, the bladder, the ureter, and the vagina. The result is a sort of desmoplastic lesion 
in the form of nodules or plaques comprising the three constituents, the mucosal, the fibrotic, and 
the smooth muscular one (44). If the smooth muscular component is the histologic hallmark of deep 
endometriosis, we consider as “deep” those forms of bowel endometriosis that infiltrate at least the 
muscular layer of the considered intestinal tract (1).  
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 Responsiveness to gonadal steroids of the endometrium within deep bowel lesions is the 
prerequisite for medical therapy aimed at inducing metabolic quiescence of ectopic glands. Noël et 
al. demonstrated that progesterone receptors were present in major histologic components of colon 
endometriosis, including the smooth muscle fibers (45). Thus, hormonal treatments should exert an 
effect on two out of the three components of deep endometriosis, that is, the ectopic endometrial 
mucosa, and the smooth muscle fibers infiltrated by it. On the other hand, a major effect of medical 
therapies on the fibrotic component appears unlikely, although an influence of progestins on fibrosis 
remodeling during time cannot be excluded, due to their demonstrated anti-inflammatory 
properties (46,47).  
 Two pathogenic mechanisms explain pain associated with deep endometriotic lesions, i.e., 
chronic inflammation deriving from the metabolic activity of ectopic endometrium, and secondary 
fibrosis with embedding of endometriotic glands into scar tissue (15,30). Recurring release of 
mediators of inflammation, such as prostaglandins and cytokines, may cause a functional-type, 
mostly cyclic pain, such as irritative-type intestinal symptoms, whereas occlusive-type intestinal 
symptoms are generally the mechanical consequence of fibrotic tissue retraction, but they may be 
influenced also by inflammatory changes of bowel wall nodules (3,6,7).  
Overall, the quality of the evidence on the effect of hormonal therapies as an alternative to 
surgery for symptomatic bowel endometriosis is suboptimal. Mainly non-comparative studies are 
available. Moreover, diverse compounds or combination of compounds have been used with very 
different durations of treatment. The exact location of intestinal endometriosis was not 
systematically indicated. Outcomes have been measured using different questionnaires and scales, 
thus rendering comparisons difficult. Scoring systems to measure pelvic dysfunction and quality of 
life in women with endometriosis should be standardized (48). Good-quality, comparative 
effectiveness research is seriously needed to more precisely define the respective impact of medical 
treatment and extirpative surgery in the long-term management of patients with symptomatic 
bowel endometriosis. In the words of Riiskjær et al. (48) "the indication for surgery in bowel 
endometriosis is almost always relative" and "this makes selection of indications for surgery and 
comparison of treatment modalities and results important".  
To this aim, randomized, controlled trials may appear preferable, but adequately designed, 
prospective parallel cohort studies may also be conducted, especially when women are not prone to 
receive randomly such diverse treatments, and prefer to take part in the medical decision by 
choosing their preferred alternative based on their priorities after detailed and impartial information 
(29,49). In fact, the two options cannot be put on the same level, because the respective balances 
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between potential benefits and potential harms are hardly comparable in the absence of severe sub-
occlusion, thus questioning the therapeutic equipoise that is ethically needed for randomization. On 
the other hand, the shared decision-making may be unduly influenced by physician's empathy, own 
beliefs, and a priori conviction, thus potentially undermining the scientific foundation on which the 
process should be based. 
In everyday practice the real query may not be which of the two treatments is more 
effective in absolute terms, but instead to what extent a satisfactory improvement of bowel 
symptoms is achievable with medical therapy when surgery is considered the standard treatment 
and, consequently, which is the probability of undergoing surgery anyway because of failure of 
hormonal manipulation. In this regard, the cohort studies by Egekvist et al. (35) and Vercellini et al. 
(29) are encouraging, as the majority of patients who used hormonal medications on a long-term 
basis eventually avoided surgery and were satisfied with their treatment as pain and bowel 
symptoms substantially improved.  
In spite of the limited quantity and quality of the findings provided in published reports, and 
while waiting for future better-designed studies, the data included in the present review constitute 
the only available evidence on which patients and caring gynecologists can base their shared 
decisions now. Medical treatment for bowel endometriosis may constitute a therapeutic alternative 
when established intestinal fibrotic stenosis with severely sub-occlusive symptoms are absent 
(2,3,6). Bowel occlusion is likely when wall infiltration is associated with intestinal fixed, strict 
angulation, or when the lumen is intrinsically narrow, such as in cases of involvement of the last ileal 
loop and the ileocecal valve (50,51). The practical issue here is defining when medical therapy is 
advantageous over surgery, taking into consideration that, if chosen, hormonal treatments should 
be continued for many years, as drugs control endometriosis but do not definitively cure it (28,31). 
In this regard, the untoward effects of different medications should be adequately described. As an 
example, progestins are frequently associated with bloating, weight gain, and irregular bleeding, 
especially in women with uterine adenomyosis. This may adversely impact on treatment adherence 
and, on the long term, induce patients to request surgery. This important aspect must be clarified 
during counseling, together with the fact that also conservative surgery as an isolated measure does 
not guarantee definitive symptoms relief (19,20,52).  
 Published data consistently suggest that several hormonal medications can control most 
symptoms associated with colorectal endometriosis, provided the relative bowel lumen stenosis is 
less than 60% (10-12,29,32). In particular, patients with irritative-type symptoms appear to respond 
significantly better than those with constipation, which may originate also from altered innervation. 
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The resolution of cyclic inflammation due to intra- and peri-lesional micro-hemorrhages may explain 
the effect on irritative complaints, whereas the observed decrease in nodule size under medical 
treatment may partially relieve the reduction in lumen caliber of the affected bowel tract. Overall, 
about two thirds of women were satisfied with the treatment received, independently of the drug 
used. Progestins are the compound supported by the largest body of evidence. The addition of 
aromatase inhibitors or, alternatively, the use of GnRH agonists, do not seem to be associated with 
better outcomes. Given the similar efficacy of the various drugs evaluated in women with colorectal 
endometriosis, priority should be given to safety, tolerability, and costs when choosing among 
different medical alternatives. In this regard, progestins appear to offer the best overall therapeutic 
profile, especially considering that medications may be used for very long periods of time.  
 Recently Casper questioned the role of OCs in the management of endometriosis based on 
the hypothesis that, owing to the supra-physiologic estrogen content, these combinations may not 
adequately suppress lesions and control symptoms (46). Although some literature data suggest that 
OCs may be safely used in women with colorectal endometriosis (12,29), bowel occlusion during 
treatment with estrogen-progestin combinations has been reported (38). Therefore, when treating 
women with symptomatic intestinal endometriosis, it may be wiser to use progestin monotherapies 
rather than OCs in order to minimize the risk of occlusion, (31). An algorithm for the management of 
non-occlusive colorectal endometriosis is suggested (Figure 3), based on the idea that, in women not 
seeking a natural conception, medical treatment may be considered as the first line of treatment, 
with surgery reserved to those patients not responding to, not tolerating, or with contraindications 
to progestins. 
 Medical therapy must be evaluated with caution when managing women who will seek a 
conception in the short term. In fact, some cases of large bowel occlusion or perforation as well as 
hydroureteronephrosis have been reported during pregnancy (53-55). Thus, the hormonal milieu of 
gestation may not guarantee the same lesion control usually observed during medical treatment. 
Surgery should be discussed also before undertaking in-vitro fertilization, as similar complications 
have been observed during ovarian stimulation (56,57). Abdominal procedures for complicated 
colorectal endometriosis in presence of a gravid uterus may reveal technically demanding and risky 
for both the mother and the fetus (58,59). Thus, women with sub-occlusive forms seeking pregnancy 
in the future should be thoroughly informed about the risks of not undergoing prior bowel surgery, 
and should be referred to tertiary care endometriosis centers where expert abdominal surgeons are 
available for pre-conception evaluation and advice. Unfortunately, except bowel occlusion, there is 
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currently no robust evidence demonstrating that prophylactic surgery reduces substantially the risk 
of other major complications during in-vitro fertilization and pregnancy. 
  In conclusion, long-term treatment with a progestin should always be included among the 
therapeutic options for women with non-severely sub-occlusive bowel endometriosis not seeking a 
conception. Given the dramatically different safety profiles, medical treatment and surgery may not 
be proposed as an “either/or” decision, but rather as a “step-up” decision, where surgery may be 
indicated as a second step only in those patients not responding to, not tolerating, or with 
contraindications to progestins. Women should be informed in detail about the potential benefits 
and potential harms of undergoing surgical removal of intestinal endometriosis and of attempting 
long-term lesion and symptom control with medical therapies (60). The final decision should be 
shared together with the woman, respecting her preferences and priorities.  
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FIGURE LEGENDS 
Table 1. Effect of aromatase inhibitors, estrogen-progestins, gonadotropin releasing hormone 
agonists (GnRHa) and progestins as assessed in studies on the treatment of bowel endometriosis 
(literature data, 2000–2018) a. 
 
Figure 1. Double-contrast barium enema showing an endometriotic stenosis of the recto-
   sigmoid junction (arrows). 
 
Figure 2. Colonoscopy showing an endometriotic nodule infiltrating the sigmoid wall and 
   protruding into the bowel lumen. 
 
Figure 3.  Suggested algorithm for a symptom-based management of large bowel 
endometriosis in women not seeking a natural conception. US = ultrasonography; 
MRI = magnetic resonance imagining; CT = computed tomography; GI = gastro-
intestinal 
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Table 1. Effect of aromatase inhibitors, estrogen-progestins, gonadotropin releasing hormone agonists (GnRHa) and progestins as assessed in studies on the 
treatment of bowel endometriosis (literature data, 2000–2018) a 
 
Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
Porpora et 
al., 2006 
(36) 
Case report 1 Sigmoid lesion Leuprolide 
acetate 3.75 
mg/28 days i.m.  
3 months NR NR Disappearance of 
symptoms after the 
first injection. At 6-
months follow-up 
colonoscopy 
disappearance of 
bowel lesion. No 
recurrence of bowel 
lesion at follow-up 
colonoscopy 
(performed every year 
for 2 years) 
Ferrero et 
al., 2010 
(10) 
Prospective 
case series 
18 Proximal rectum 
(n = 4); 
rectosigmoid 
junction (n = 5); 
sigmoid lesion (n 
= 9) 
Triptorelin 11.25 
mg/3 months 
i.m. + tibolone 
2.5 mg/day per 
os 
12 months  Hot flushes (33) 
Vaginal bleeding 
(33) 
Sweating episodes 
(17) 
Vaginal dryness 
and superficial 
dyspareunia (11) 
Nervousness and 
Patient self 
judgements of 
changes in 
gastrointestinal 
symptoms using 
a 5-point Likert 
scale 
(significantly 
improved, 
improved, 
unchanged, 
Significant 
improvement of pain 
symptoms. 
Improvement in 
intestinal function in 
patients with 
symptoms mimicking 
IBS-D. At 12-month 
assessment 13 (72%) 
women were very 
satisfied or satisfied, 2 
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Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
irritability (11) 
Weight gain (11) 
Sleeplessness (6) 
Fatigue (6) 
Difficulty in 
concentration (6) 
worsened, 
significantly 
worsened) 
(11%) were uncertain, 
and 3 (17%)were 
dissatisfied 
Ferrero et 
al., 2010 
(11) 
Prospective 
case series 
40 Proximal rectum 
(n = 10); 
rectosigmoid 
junction (n = 12); 
sigmoid lesion (n 
= 18) 
NETA 2.5 
mg/day per osb 
12 months Worsening of 
constipation (7.5) 
Breakthrough 
bleeding (5)   
Weight gain (5) 
Spotting (2.5) 
Depression (2.5) 
Migraine attacks 
(2.5) 
 
Symptom 
analogue scale 
questionnaire (1 
indicated the 
absence of the 
symptom; 10 
indicated the 
highest severity 
of the symptom) 
regarding each 
gastrointestinal 
symptom. 
Significant 
improvement of dysm, 
dysp, CPP, dyschezia 
and diarrhea. No 
significant 
improvement in 
patients with 
constipation, 
abdominal bloating 
and feeling of 
incomplete evacuation 
after bowel 
movements. 60% of 
patients were satisfied 
or very satisfied with 
the treatment. 
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Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
Ferrero et 
al., 2010 
(32) 
Prospective 
case series 
6 Proximal rectum 
(n = 2); 
rectosigmoid 
junction (n = 2); 
sigmoid lesion (n 
= 2) 
Letrozole 2.5 
mg/day + NETA 
2.5 mg/day per 
os 
6 months Breakthrough 
bleeding (17) 
Weight gain (17) 
Joint pain (17) 
Decreased libido 
(17) 
Symptom 
analogue scale 
questionnaire (1 
indicated the 
absence of the 
symptom; 10 
indicated the 
highest severity 
of the symptom) 
regarding each 
gastrointestinal 
symptom. 
Significant 
improvement of dysm, 
dysp, CPP, and 
gastrointestinal 
symptoms. 
High satisfaction rate 
at the end of study 
period (67% of 
women were satisfied 
or very satisfied). 
No changes in BMD 
were identified. 
Harada et 
al., 2011 
(33) 
Retrospective 
case series 
4 Rectosigmoid 
junction (n = 4) 
DNG 2 mg/day 
per os 
12 months Spotting (75)                          
Hot Flushes (50)          
Gastralgia (25)            
Depression (25) 
NR Significant 
improvement of pain 
symptoms and 
reduction in nodule 
size.  
Ferrari et 
al., 2012 
(12) 
Prospective 
case series 
22c Proximal rectum, 
n = 14; recto-
sigmoid 
junction/sigmoid, 
n = 8 
 
Continuous low-
dose 
monophasic OC 
(EE 15 μg + 
gestodene 60 
μg)/day     
12 months Breakthrough 
bleeding (38) 
Weight gain (23) 
Headache (12) 
Decreased libido 
(8)  
Dyschezia was 
assessed by 0-10 
visual analog 
pain scale (0 
indicated the 
absence of the 
symptom; 10 
indicated the 
Significant 
improvement of dysm, 
dysp, CPP, and 
dyschezia.  
Significant reduction 
of nodule size after 12 
months of treatment. 
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Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
highest severity 
of the symptom) 
High satisfaction rate 
at the end of study 
period (69% of 
women were satisfied 
or very satisfied). 
Tamura et 
al., 2013 
(37) 
Case report  1 Proximal rectum 
and rectosigmoid 
junction 
Cyclic DNG 2 
mg/day per os 
22 months Spotting NR Significant 
improvement of pain 
and gastrointestinal 
symptoms. 
Disappearance of 
bowel lesion at 
biopsy. Reduction of 
CA-125 serum levels. 
Roman et 
al., 2015 
(34) 
Prospective 
case series 
70 Lesions located 
within 15 cm 
from the anal 
verge. 
Triptorelin 
acetate11.25 mg 
i.m. + estradiol 
0.1%/day 
percutaneous 
3.4 ± 1.8 
months 
NR GIQLI (ref. 40), 
Bristol stool 
scale (ref. 41), 
KESS (ref. 42), 
Fecal 
Incontinence 
Quality of Life 
index (ref. 43)  
Improvement of cyclic 
digestive complaints 
in more than half of 
patients. Constipation 
and non-cyclic 
symptoms were 
improved in in less 
than a third of 
patients. 
Yela et al., 
2015 (13)  
Prospective 
case series 
16 Not specified DNG 2 mg/day 
per os 
6 months Headache 
Acne 
Dyschezia was 
assessed by 0-10 
visual analog 
pain scale (0 
Significant 
improvement of pain 
symptoms (dysm, 
dysp, CPP, and 
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Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
Decreased libido 
Breast pain  
Hair loss 
Nausea/vomit 
Bloating 
Vaginal dryness 
indicated the 
absence of the 
symptom; 10 
indicated the 
highest severity 
of the symptom) 
dyschezia). No 
significant changes in 
volume size of 
endometriotic nodules. 
No significant changes 
in QoL and sexual 
function. 
Millochau et 
al., 2016 
(38) 
Case report  1 Sigmoid colon Cyproterone 
acetate 50 
mg/day per os + 
Estradiol 0.5 
mg/day 
percutaneous gel 
(first 2 years)  
Continuous 
medium dose 
OC (EE 30 g + 
LNG 150 
g)/day        
(until the end of 
follow-up)  
4 years  With cyproterone 
acetate:                    
Mood changes 
GIQLI (ref.40), 
KESS (ref.42) 
With cyproterone 
acetate partial 
amelioration of 
gastrointestinal 
symptoms, with 
unchanged 
constipation and 
bloating.  
With OC worsening of 
gastrointestinal 
symptoms and 
enlargement of bowel 
nodule at MRI and 
CT-based virtual 
colonoscopy. 
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Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
Leonardo-
Pinto et al., 
2017 (14) 
Prospective 
case series 
30 Not specified DNG 2 mg/day 
per os 
12 months Headache (63) 
Breast pain (43) 
Decreased libido 
(43) 
Nausea/vomiting 
(23) 
Intestinal pain 
was assessed by 
0-10 visual 
analog pain scale 
(0 indicated the 
absence of the 
symptom; 10 
indicated the 
highest severity 
of the symptom) 
Significant 
improvement of pain 
symptoms (dysm, 
dysp, CPP, bowel 
pain) and QoL. No 
significant changes in 
volume size of 
endometriotic nodules. 
Ng et al., 
2017 (39) 
Case report 1 Proximal rectum 
and rectosigmoid 
junction 
DNG 2 mg/day 
per os 
6 months Spotting NR Significant 
improvement of pain 
(dysm, dysp) and 
gastrointestinal 
symptoms. 
Vercellini et 
al., 2017 
(29) 
Retrospective 
cohort study 
50d Proximal rectum, 
rectosigmoid 
junction, and 
sigmoid colon 
Continuous low-
dose 
monophasic OC 
(EE 15 μg + 
gestodene 60 
μg)/day; NETA 
2.5 mg/day per 
os; DNG 2 
mg/day per os 
40 [18-60] 
months 
Weight gain (32), 
decreased libido 
(18), bloating (16), 
vaginal dryness 
(16), headache (10), 
and mood changes 
(4) 
KESS; 
Intestinal 
symptoms were 
assessed by 0-10 
numerical rating 
scale scale (0 
indicated the 
absence of the 
symptom; 10 
indicated the 
highest severity 
At final follow-up, 14 
patients were very 
satisfied, 22 satisfied, 
5 neither satisfied nor 
dissatisfied, 7 
dissatisfied, and 2 
very dissatisfied. 
Significant 
improvements of 
bowel symptoms as 
assessed by both the 
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Source Study design Patients 
enrolled 
(n) 
Location of 
bowel 
endometriotic 
nodules  
Study drug Treatment 
period 
Adverse effects 
(%) 
Questionnaires 
adopted to 
evaluate bowel 
symptoms 
Outcome 
of the symptom) KESS questionnaire 
and the numerical 
rating scale. 
 
a Egekvist et al., 2017 (35) was not included in the table because the exact number of patients who used the different medical treatments (OC, LNG-
intrauterine   
  device or oral progestins), the adverse effects associated with their use, and the different outcomes in terms of pain symptoms or gastrointestinal symptoms  
  variation could not be extracted from the published report.  
b In case of breakthrough bleeding the daily oral dose of NETA was doubled. 
c Patients with medium-low rectum nodules (n = 4) are excluded. 
d Only patients who chose medical treatment are here reported. 
 
BMD = bone mineral density; CPP = chronic pelvic pain; DNG = dienogest; dysm = dysmenorrhea; dysp = dyspareunia; EE = ethinyl-estradiol; GIQLI = 
Gastro Intestinal Quality of Life Index; IBS-D = diarrhea-predominant irritable bowel syndrome; KESS = Knowles-Eccersley-Scott-Symptom Questionnaire; 
LNG = levonorgestrel; MRI = magnetic resonance image; NETA = nor-ethisterone acetate; NA = not applicable; NR = not reported; OC = oral contraceptive. 
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